Open Clinical Trials

Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors

Purpose of this clinical trial:

The goal of this clinical research study is to establish the safety of simultaneous infusions of methotrexate and etoposide into the fourth ventricle of the brain or resection cavity in patients with recurrent malignant posterior fossa brain tumors. Patients' disease must have originated in the posterior fossa of the brain.

Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors

Purpose of this clinical trial:

The main purpose of this study is to determine if infusions of methotrexate into the fourth ventricle of the brain in combination with IV administration of topotecan and cyclophosphamide is effective in reducing disease in the brain and spine for patients with recurrent or progressive brain tumors.

MV-NIS: Modified Measles Virus for Children and Young Adults with Recurrent ATRT

Purpose of this clinical trial:

The main purpose of MV-NIS is to study the effects of the safety and appropriate dose level of the modified measles virus (MV-NIS) in children and young adults with recurrent (disease has returned) medulloblastoma or ATRT

SJATRT: Phase II Study of Alisertib Therapy for Rhabdoid Tumors

PBTC-051: Phase I Study of APX005M in Pediatric CNS Tumors

Purpose of this clinical trial:

The main purpose of this study is to determine the best dose and side effects of a new drug called APX005M in treating children and young adult patients with brain cancer that is growing, spreading or getting worse.

Sponsor Site Principal Investigator:

Santhosh Upadhyaya, MD

Phone: 901-595-5175

Email: santhosh.upadhyaya@stjude.org

Sponsor Site Coordinator:

Tabatha Doyle, RM

Phone: 901-595-2544

Email: tabatha.doyle@stjude.org

SJDAWN: Phase I Study of Molecularly-Driven Doublet Therapies

Sponsor Site Principal Investigator:

Giles Robinson, MD

Phone: 901-595-4055

Email: giles.robinson@stjude.org

Sponsor Site Coordinator:

Tabatha Doyle, RM

Phone: 901-595-2544

Email: tabatha.doyle@stjude.org

BrainChild-01: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

Purpose of this clinical trial:

The main purpose of this study is to determine the side effects and best dose of HER2-specific chimeric antigen receptor (CAR) T cell immunotherapy in treating patients with brain tumors that have come back or does not respond to treatment (recurrent or refractory disease).

BrainChild-02: EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

Purpose of this clinical trial:

The main purpose of this study is to determine if T-cell therapy is safe to give to children and young adults with recurrent (disease has returned) or refractory EGFR positive central nervous system (CNS) tumors, including ATRT, and what dose of this therapy is best.

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Purpose of this clinical trial:

This is a standard of care treatment guideline for high risk or relapsed solid tumors or CNS tumors consisting of a busulfan, melphalan, thiotepa conditioning (for solid tumors) or carboplatin and thiotepa conditioning (for CNS tumors) followed by an autologous peripheral blood stem cell transplant.

PVSRIPO: Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children

Purpose of this clinical trial:

The main purpose of PVSRIPO is to study the safety and appropriate dose level of the oncolytic poliovirus (PV) immunotherapy with PVSRIPO) in children and young adults with recurrent (disease has returned) grade IV ATRT.

Tazemetostat: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Purpose of this clinical trial:

The main purpose of this study is to establish the safety and best possible dose of tazemetostat for patients with relapsed or refractory INI1- negative tumors or synovial sarcoma.

Hope4ATRT Foundation

is a research entity of

Out of Zion, Inc.

Mailing Address: 

P.O. Box 6130   New York, NY  10150